NRX Pharmaceuticals Inc Cash Flow Conversion Efficiency
NRX Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, NRX Pharmaceuticals Inc (NRXP) has a cash flow conversion efficiency ratio of 0.112x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.89 Million) by net assets ($-25.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of NRX Pharmaceuticals Inc (2017–2024)
Cash flow conversion efficiency of NRX Pharmaceuticals Inc from 2017 to 2024. This chart illustrates how NRX Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NRX Pharmaceuticals Inc stock quote for real-time trading data and today's change.
NRX Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
NRX Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
NRX Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRX Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market value of NRX Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Herige SA
PA:ALHRG
|
0.119x |
|
Skane mollan AB
ST:SKMO
|
0.022x |
|
S Connect Co. LTD
KQ:096630
|
0.101x |
|
DHP Korea Co. Ltd
KQ:131030
|
0.035x |
|
K Wave Media Ltd.
NASDAQ:KWM
|
655.501x |
|
Skolon AB
ST:SKOLON
|
-2.083x |
|
Sumber Energi Andalan Tbk PT
JK:ITMA
|
-0.002x |
|
Edelteq Holdings Berhad
KLSE:0278
|
0.007x |
Annual Cash Flow Conversion Efficiency for NRX Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of NRX Pharmaceuticals Inc from 2017 to 2024. Review financial agility of NRX Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-23.22 Million | $-10.64 Million | 0.458x | -75.19% |
| 2023-12-31 | $-11.73 Million | $-21.66 Million | 1.846x | +134.40% |
| 2022-12-31 | $7.41 Million | $-39.76 Million | -5.366x | -196.10% |
| 2021-12-31 | $20.81 Million | $-37.70 Million | -1.812x | -3601.91% |
| 2020-12-31 | $-43.77 Million | $-2.27 Million | 0.052x | +292.57% |
| 2019-12-31 | $29.50 Million | $-792.73K | -0.027x | -294.90% |
| 2018-12-31 | $69.54 Million | $-473.19K | -0.007x | -248.09% |
| 2017-12-31 | $69.47 Million | $-135.81K | -0.002x | -- |
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in p… Read more